Analysts expect MapLight Therapeutics, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.85 M | 2.21 M | 2.53 M | 8,541.34 | |||||||||||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.54 M | 2.08 M | 2.25 M | 7,334.70 | |||||||||||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.70 M | 2.14 M | 2.39 M | 7,938.02 |
Analysts expect MapLight Therapeutics, Inc. to report earnings per share of -1.37 for Q2 26, against a range of -1.43 to -1.31. The most recent reported quarter, Q1 26, came in at -1.34, a 34.0% miss against the -1.00 consensus.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.14 | -37.18 | -2.47 | -1.34 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | -1.54 | -0.88 | -0.96 | -1.31 | -1.23 | -1.23 | -1.15 | -1.13 | -0.75 | 6.25 | -2.11 | |||||||||||
| Low Estimate | - | -1.82 | -1.00 | -1.04 | -1.43 | -1.37 | -1.33 | -1.25 | -1.21 | -0.81 | 5.35 | -2.51 | |||||||||||
| Consensus Estimate | - | -1.68 | -0.94 | -1.00 | -1.37 | -1.30 | -1.28 | -1.20 | -1.17 | -0.78 | 5.80 | -2.31 |